Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026
Calpain inhibition by calpeptin modulates adipocyte lipid metabolism and secretome-mediated inflammatory crosstalk with hepatocytes.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Matilainen Johanna, Foster Sanni, Berg Viivi, Mustonen Anne-Mari, Oikari Sanna, Rilla Kirsi, Käkelä Reijo, Sihvo Sanna P, Nieminen Petteri
Аннотация
OBJECTIVE: Calpeptin, a calpain inhibitor with potential for treating inflammatory diseases, reduces extracellular vesicle (EV) secretion. While adipose tissue is a recognized target of calpeptin, its effects on lipid metabolism remain unknown. We investigated calpeptin's impact on fatty acid (FA) profiles and metabolic pathways in human Simpson-Golabi-Behmel Syndrome adipocytes and their EVs.
METHODS: Adipocytes were treated with 25 or 50 µM calpeptin, and EVs were isolated from conditioned media (CM) by ultracentrifugation. Immortalized human hepatocytes (IHHs) were pre-treated with 0 or 400 µM palmitic acid (PA) and subsequently exposed to CM from calpeptin-treated adipocytes. Total lipid FA composition was determined by gas chromatography-mass spectrometry, and gene expression with RNA-sequencing and qPCR, followed by univariate and multivariate statistics and pathway analyses.
RESULTS: Calpeptin reduced EV secretion and arachidonic acid proportions in adipocytes, while also perturbing key metabolic pathways, including those of the dietarily essential polyunsaturated FAs (PUFAs). Potential biomarker candidates associated with calpeptin included C20-22 PUFAs (adipocytes) and 23:0 (EVs). Both PA and the secretome from calpeptin-treated adipocytes induced pro-inflammatory responses in IHHs.
CONCLUSION: The findings suggest that calpeptin may modulate adipocyte lipid metabolism and EV secretion, with associated inflammatory responses in hepatocytes likely mediated by adipocyte‑derived secreted factors. These observations warrant further investigation into the potential adverse effects of calpeptin in the context of metabolic diseases.
METHODS: Adipocytes were treated with 25 or 50 µM calpeptin, and EVs were isolated from conditioned media (CM) by ultracentrifugation. Immortalized human hepatocytes (IHHs) were pre-treated with 0 or 400 µM palmitic acid (PA) and subsequently exposed to CM from calpeptin-treated adipocytes. Total lipid FA composition was determined by gas chromatography-mass spectrometry, and gene expression with RNA-sequencing and qPCR, followed by univariate and multivariate statistics and pathway analyses.
RESULTS: Calpeptin reduced EV secretion and arachidonic acid proportions in adipocytes, while also perturbing key metabolic pathways, including those of the dietarily essential polyunsaturated FAs (PUFAs). Potential biomarker candidates associated with calpeptin included C20-22 PUFAs (adipocytes) and 23:0 (EVs). Both PA and the secretome from calpeptin-treated adipocytes induced pro-inflammatory responses in IHHs.
CONCLUSION: The findings suggest that calpeptin may modulate adipocyte lipid metabolism and EV secretion, with associated inflammatory responses in hepatocytes likely mediated by adipocyte‑derived secreted factors. These observations warrant further investigation into the potential adverse effects of calpeptin in the context of metabolic diseases.